IV Iron Replacement for Anemia
This trial is testing if giving iron through an IV can help cancer patients who are getting chemotherapy before surgery. The goal is to improve their blood health and reduce the need for blood transfusions. Intravenous iron therapy has been shown to be advantageous in treating anemia and reducing the need for blood transfusions in cancer patients.
Protein Therapeutics
Luspatercept for Myelodysplastic Syndrome-related Anemia
This trial will test if luspatercept can reduce the need for blood transfusions in participants with anemia caused by MDS or MDS/MPN. It will also assess the safety and tolerability of luspatercept.
Popular Filters
Trials for Iron-Deficiency Anemia Patients
Protein Therapeutics
Luspatercept for Myelofibrosis
This trial is studying how well luspatercept works in treating patients with myeloproliferative neoplasm-associated myelofibrosis and anemia who are on concomitant Janus kinase 2 inhibitor therapy and who require red blood cell count transfusions.
Chemotherapy
INCB000928 + Ruxolitinib for Myelofibrosis
This trial is testing a new drug called INCB000928, either alone or with ruxolitinib, to see if it is safe and effective. It targets people with Myelofibrosis who need regular blood transfusions or have severe anemia. The goal is to see if the drug can reduce the need for transfusions and improve anemia symptoms.
Erythropoiesis-Stimulating Agent
Darbepoetin for High Blood Pressure in Chronic Kidney Disease
This trial is testing whether erythropoietin (EPO) therapy can raise diastolic blood pressure in anemic patients with chronic kidney disease. The study will measure the effects of EPO therapy at 12 weeks after treatment, and will enroll 160 subjects.
Trials for Myelodysplastic Syndrome Patients
Protein Therapeutics
Luspatercept for Myelofibrosis
This trial is studying how well luspatercept works in treating patients with myeloproliferative neoplasm-associated myelofibrosis and anemia who are on concomitant Janus kinase 2 inhibitor therapy and who require red blood cell count transfusions.
Chemotherapy
INCB000928 + Ruxolitinib for Myelofibrosis
This trial is testing a new drug called INCB000928, either alone or with ruxolitinib, to see if it is safe and effective. It targets people with Myelofibrosis who need regular blood transfusions or have severe anemia. The goal is to see if the drug can reduce the need for transfusions and improve anemia symptoms.
Erythropoiesis-Stimulating Agent
Darbepoetin for High Blood Pressure in Chronic Kidney Disease
This trial is testing whether erythropoietin (EPO) therapy can raise diastolic blood pressure in anemic patients with chronic kidney disease. The study will measure the effects of EPO therapy at 12 weeks after treatment, and will enroll 160 subjects.
Phase 3 Trials
Protein Therapeutics
Luspatercept for Myelofibrosis
This trial is studying how well luspatercept works in treating patients with myeloproliferative neoplasm-associated myelofibrosis and anemia who are on concomitant Janus kinase 2 inhibitor therapy and who require red blood cell count transfusions.
Blood System
INTERCEPT Treated RBCs for Anemia
This trial is testing a special type of blood transfusion for patients having complex heart surgery. The new treatment aims to make blood transfusions safer by reducing infections and complications. The study will evaluate if this new method works effectively.
Pathogen Reduction System
INTERCEPT Blood System for Blood Transfusion Safety
This trial is designed to study the safety and efficacy of the INTERCEPT Blood System for pathogen reduction of red blood cells in comparison to conventional methods. If successful, the system may be made available in areas where transfusion-transmissible infections are common.
Bruton's Tyrosine Kinase (BTK) Inhibitor
Ibrutinib + Rituximab for Chronic Lymphocytic Leukemia
This trial is studying ibrutinib and rituximab compared to fludarabine phosphate, cyclophosphamide, and rituximab to see which works better in treating patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Trials With No Placebo
Chemotherapy
INCB000928 + Ruxolitinib for Myelofibrosis
This trial is testing a new drug called INCB000928, either alone or with ruxolitinib, to see if it is safe and effective. It targets people with Myelofibrosis who need regular blood transfusions or have severe anemia. The goal is to see if the drug can reduce the need for transfusions and improve anemia symptoms.
Erythropoiesis-Stimulating Agent
Darbepoetin for High Blood Pressure in Chronic Kidney Disease
This trial is testing whether erythropoietin (EPO) therapy can raise diastolic blood pressure in anemic patients with chronic kidney disease. The study will measure the effects of EPO therapy at 12 weeks after treatment, and will enroll 160 subjects.
Blood System
INTERCEPT Treated RBCs for Anemia
This trial is testing a special type of blood transfusion for patients having complex heart surgery. The new treatment aims to make blood transfusions safer by reducing infections and complications. The study will evaluate if this new method works effectively.
Pathogen Reduction System
INTERCEPT Blood System for Blood Transfusion Safety
This trial is designed to study the safety and efficacy of the INTERCEPT Blood System for pathogen reduction of red blood cells in comparison to conventional methods. If successful, the system may be made available in areas where transfusion-transmissible infections are common.
View More Related Trials
Frequently Asked Questions
Introduction to anemia
What are the top hospitals conducting anemia research?
Anemia, a condition characterized by a deficiency of red blood cells or hemoglobin in the body, is an ongoing concern for patients and healthcare providers alike. In the pursuit of effective treatments and advancements in understanding this condition, several hospitals have emerged as leaders in conducting clinical trials dedicated to anemia. Cincinnati Children's Hospital Medical Center in Cincinnati has a notable presence with eight active anemia trials and a total of 19 trials conducted over time. Since initiating their first recorded trial in 2004, they have been at the forefront of research concerning this debilitating condition.
Meanwhile, the National Institutes of Health Clinical Center located in Bethesda has also made significant contributions to furthering our understanding of anemia through clinical trials. With eight active trials currently underway and 14 completed studies to their name, they are driving innovation since their initial trial on anemia commenced back in 2001.
In Portland, Oregon Health & Science University plays its part with four active anemia trials while having previously explored this condition through eight additional investigations since recording their first trial on it during 2005; similarly making strides towards discovering new treatment options for those affected by anemia.
Children's Hospital Los Angeles joins the ranks with three ongoing trials focused on fighting against anemia while contributing insights from previously held eight experiments meant tackling similar cases since initial steps taken back during early days around till year elapsed untilin2006.
Lastly yet importantly situated within Seattle is University of Washington which despite comparatively fewer numbers boasts three current clinical tests addressing concerns around combatinganemiawhile having carved paths forward via past four undertaken initiatives only commencing recently when early stages began being set up as recent as2016. These leading hospitals represent beacons hope not only for individuals living with this challenging condition but also demonstrate that concerted efforts towards advancing knowledge surroundinganemiacan bring about substantial progress ensuring better futures for countless patients worldwide
Which are the best cities for anemia clinical trials?
When it comes to anemia clinical trials, several cities stand out as hotspots for research and development. Los Angeles, California leads the way with 17 active trials focusing on treatments such as standard of care iron, Ibrutinib, and Fostamatinib disodium. New york, New York follows closely behind with 15 ongoing studies exploring ACE-536, liberal transfusion strategies, and Etavopivat 400 mg QD daily. Philadelphia, Pennsylvania and Bethesda, Maryland tie in third place with 13 active trials each investigating various interventions like M281 and Eltrombopag. Notably, Cincinnati, Ohio also shows promise with 12 active trials studying hydroxyurea and other potential breakthrough therapies. These cities offer individuals affected by anemia access to cutting-edge clinical trials that pave the way for advancements in treatment options and improved quality of life.
Which are the top treatments for anemia being explored in clinical trials?
Clinical trials are continuously exploring new treatments for anemia, offering hope to those affected by this condition. Among the top contenders currently being investigated are:
- Eltrombopag: Featured in five active anemia trials and a total of 13 all-time trials since its initial listing in 2009.
- Hydroxyurea: Under investigation in four ongoing anemia trials and has been involved in a cumulative 19 all-time trials since its introduction in 2000.
- INCB000928: Although relatively new on the scene, with only two active anemia trials and two all-time listed since 2021, INCB000928 shows exciting potential.
- Fludarabine: Participating in two current anemia studies and boasting participation across 29 all-time clinical trials since being first listed over two decades ago.
These innovative approaches hold promise for revolutionizing the management of anemia, potentially improving outcomes for patients around the world.
What are the most recent clinical trials for anemia?
Recent clinical trials have shed light on potential breakthroughs in the treatment of anemia. Among these studies, daprodustat has shown promise in managing this condition when compared to standard of care iron therapies. Additionally, the use of transfusion and phlebotomy in patients with anemia is being explored as a viable option for intervention. In parallel, researchers are investigating the efficacy and safety of experimental -Bitopertin as a potential treatment for anemia. As we await further results from ongoing trials, these findings provide hope that improved strategies for addressing anemia may be on the horizon.
What anemia clinical trials were recently completed?
Multiple recent clinical trials have made significant strides in advancing the understanding and treatment of anemia. In November 2021, Annexon, Inc. completed a trial investigating ANX005, offering potential insights into this challenging condition. Preceding that, The University of Texas Medical Branch successfully concluded their investigation on Iron dextran in October 2021. Furthermore, USRC Kidney Research completed a trial studying Ferric Citrate 1 gram Oral Tablet in June 2021. These recent achievements demonstrate the dedication of researchers and hold promise for improving outcomes for individuals affected by anemia.